Cleft Palate and Velopharyngeal Insufficiency-Natural History and Evolution of Treatment Options.
Mazzola RF., Cohen M., Mazzola IC.
Narrative Review, published in J Craniofac Surg (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Craniofac Surg (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40029614
- DOI
- 10.1097/SCS.0000000000010381
- Citations
- 1
Abstract (original English)
Cleft palate closure, first carried out by the German Gräfe (1787 - 1840) and by the Frenchman Roux (1780 - 1854) in 1816 and in 1818, respectively, and later improved by the German Langenbeck (1810 - 1887) in 1861, did not always achieve successful outcome regarding speech. Often the velum remained too short or reopened partially, without reaching the posterior pharyngeal wall and maintaining an air escape through the nose. This condition is known as hypernasality or velopharyngeal insufficiency, whose term was coined by the French otolaryngologist Lermoyez (1858 - 1929) in 1892. To improve speech and minimize hypernasality, numerous solutions have been proposed over the years by different surgeons. Among them by the German surgeon Passavant (1813 - 1893), who advocated either the elongation of the soft palate by suturing the palatopharyngeus muscle along the midline, beyond the uvula, or the outlining of a velopharyngeal flap, the so - called velopharyngoplasty, or the advancement of the posterior pharyngeal wall. The latter option was performed initially by positioning an implant in the retropharyngeal space. Nowadays, in the presence of medium to moderate velopharyngeal insufficiency, autologous fat, injected in the posterior pharyngeal wall, represents the solution of choice. It possesses the regenerative potential mediated by the pluripotent stem cells, present in the str
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.